Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

X
Trial Profile

Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REFRESH
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 16 May 2013 Interim data, from the first 23 patients, presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 16 May 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top